Related Experiment Video

Updated: May 3, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

11.7K

Influence of the β-fibrinogen-455G/A polymorphism on development of ischemic stroke and coronary heart disease

Lian Gu1, Wenhui Liu2, Yan Yan1

  • 1Department of Neurology, First Affiliated Hospital, Guangxi University of Chinese Medicine, Nanning, Guangxi, China.

Thrombosis Research
|January 23, 2014
PubMed

Insights

The β-fibrinogen-455G/A polymorphism is linked to increased risk of ischemic stroke (IS) and coronary heart disease (CHD). This genetic factor, particularly the A allele, shows higher susceptibility in Asian populations for IS.

Area of Science:

  • Genetics and Cardiovascular Disease
  • Molecular Epidemiology
  • Vascular Biology

Background:

  • Ischemic stroke (IS) and coronary heart disease (CHD) are leading global causes of mortality.
  • Previous studies on the β-fibrinogen-455G/A (FGB-455G/A) polymorphism and IS/CHD risk have yielded inconsistent results.

Purpose of the Study:

  • To conduct a meta-analysis investigating the association between the FGB-455G/A polymorphism and susceptibility to IS and CHD.
  • To clarify the genetic contribution of this polymorphism to vascular disorders.

Main Methods:

  • A comprehensive literature search was performed across PubMed, Embase, and four Chinese databases up to July 2013.
  • Data from 45 studies (7238 cases, 7395 controls) were analyzed using Stata 11.2.
  • Pooled odds ratios (OR) with 95% confidence intervals (CI) and cumulative meta-analysis were employed to assess genetic associations and temporal trends.

Main Results:

  • The FGB-455G/A polymorphism is associated with an increased risk of IS (OR=1.518, 95%CI=1.279-1.802) under the dominant model.
  • Subgroup analysis revealed a significantly elevated risk of IS associated with the A allele in Asians (OR=1.700, 95%CI=1.417-2.040) but not in Caucasians.
  • A significant association was also found between the FGB-455G/A polymorphism and CHD risk (OR=1.802, 95%CI=1.445-2.246).

Conclusions:

  • The FGB-455G/A polymorphism is a contributing factor to the susceptibility of individuals to ischemic stroke.
  • This genetic polymorphism also plays a role in the development of coronary heart disease.
  • The findings highlight the importance of genetic variations in fibrinogen for vascular disease risk.
Abstract

Keywords:
Coronary heart diseaseFGB-455G/A geneIschemic strokePolymorphism

More Related Videos

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.6K
High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

12.4K

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
189
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
138